Cantourage Adds Blue Dream Extracts for Pharmacy Compounding

Cantourage Group SE is expanding its product portfolio with new cannabis active ingredients in the form of a crude extract and a distillate, according to a company announcement dated September 11, 2026. The new active ingredients are intended for further processing in pharmacies, opening up additional possibilities for the preparation of patient-specific compounded medicines.

Based on the new active ingredients, pharmacies can prepare a range of dosage forms as compounded medicines, subject to the applicable legal and pharmaceutical requirements. According to the company, these may include solutions, suppositories, inhalation products (vapes) and oral dosage forms (edibles) such as gummies.

Cantourage Group SE (HIGH.DE ) (ISIN: DE000A3DSV01) describes itself as a leading European medical cannabis company. Its portfolio has so far primarily comprised cannabis flower and established extract products. The company said the new active ingredients are intended to provide pharmacies with greater flexibility in preparing individualized formulations, with the aim of giving physicians, pharmacies and patients additional options for cannabinoid-based therapies tailored to individual patient needs.

Blue Dream Genetics and the Compounding Model

Cantourage is using the “Blue Dream” cannabis genetics, which it calls well-established and widely appreciated, as the starting material for the new active ingredients. Processing the cannabis into crude extract and distillate makes these genetics available for new pharmaceutical applications and dosage forms, the company said.

The patient-specific compounded medicines themselves are prepared by pharmacies. In this way, Cantourage said, it combines the provision of standardized cannabis starting materials with the pharmaceutical expertise of pharmacies in preparing individualized formulations.

“With the introduction of crude extract and distillate, we are creating a new foundation for innovative cannabis formulations in German pharmacies,” said Philip Schetter, CEO of Cantourage Group SE. “In our view, medical cannabis does not have to be limited to flower and a small number of established dosage forms. Compounding offers the opportunity to address patients’ needs in a much more differentiated way and to make new, user-friendly product formats available.”

Cantourage said it sees an attractive additional market segment particularly in the field of individually prepared cannabis formulations. The company expects a significant proportion of this market to develop as a self-pay market. As a result, it expects demand in the segment to be less dependent on reimbursement decisions and the regulatory framework of Germany’s statutory health insurance system (GKV). The company further expects that the growing variety of available active ingredients and dosage forms can help make medical cannabis accessible to additional patient groups while also strengthening the role of pharmacies in individualized cannabis therapy.

Expopharm Launch and 2026 Financial Context

The market launch is scheduled to coincide with expopharm in Munich, where Cantourage will present the new active ingredients to a broader professional audience of pharmacists and pharmaceutical industry participants for the first time. The announcement describes expopharm as Europe’s leading trade fair for the pharmacy market.

According to the trade fair’s official website, expopharm 2026 takes place from September 15 to September 17, 2026, at Messe München. The organizer states that the three-day event brings together roughly 500 exhibitors and brands, more than 200 speakers and more than 25,000 trade visitors. expopharm is a project of Avoxa – Mediengruppe Deutscher Apotheker GmbH.

Cantourage stated that the information published in the September 11 announcement and the resulting expected contributions to revenue and earnings were already taken into account in the forecast it issued on August 31, 2026. In that release, the Management Board issued guidance for financial year 2026 for the first time, expecting consolidated revenue in a range of EUR 85 million to EUR 95 million and consolidated adjusted EBITDA in a range of EUR 10 million to EUR 12 million. The company named the increasing internationalisation of the business and the consistent focus of the German product portfolio on higher-margin segments as key drivers of the expected business performance. It said the regulatory changes currently foreseeable in the German market have been taken into account in the guidance and, based on the information currently available, are expected to have only a limited impact on business performance in the 2026 financial year.

The portfolio expansion follows Cantourage’s second-quarter report published on August 13, 2026, in which the company said EBITDA rose 45% year-on-year to EUR 2.9 million while revenue declined by around 22% to EUR 21.8 million as a result of the strategic refocusing of the German business. In that report, the company said its own brand GRAMZ. was newly launched in the German market during the quarter and that further innovative product formats are being developed under its innovation strategy, some of which are already in the testing phase.